Stephen Hahn

A Conversation with FDA Commissioner Stephen Hahn

Stephen Hahn, Esther Krofah

Dr. Hahn and the FDA are managing an unprecedented 250-treatment pipeline and 170 vaccine candidates while maintaining regulatory independence amid a surge in applications. The agency has authorized specific therapies like remdesivir and dexamethasone based on robust data analysis and is implementing clinical trial flexibilities to ensure diverse demographic inclusion. Despite the high stakes, FDA officials emphasize that safety and evidence-based decision-making remain paramount as they navigate supply chain logistics and monitor real-world outcomes for public health.